Pharmacological modulation of mitochondrial function as novel strategies for treating intestinal inflammatory diseases and colorectal cancer

Journal of Pharmaceutical Analysis, Journal Year: 2024, Volume and Issue: unknown, P. 101074 - 101074

Published: Aug. 1, 2024

Inflammatory bowel disease (IBD) is a chronic and recurrent intestinal disease, has become major global health issue. Individuals with IBD face an elevated risk of developing colorectal cancer (CRC), recent studies have indicated that mitochondrial dysfunction plays pivotal role in the pathogenesis both CRC. This review covers CRC, focusing on dysfunction, explores pharmacological targets strategies for addressing conditions by modulating function. Additionally, advancements modulation treating encompassing damage, release DNA (mtDNA), impairment mitophagy, are thoroughly summarized. The also provides systematic overview natural compounds (such as flavonoids, alkaloids, diterpenoids), Chinese medicines, microbiota, which can alleviate attenuate progression CRC In future, it will be imperative to develop more practical methodologies real-time monitoring accurate detection function, greatly aid scientists identifying effective agents through

Language: Английский

Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 142, P. 113194 - 113194

Published: Sept. 20, 2024

Language: Английский